FARXIGA
- Product NDC
- 55154-6933
- Requested package NDC
- 55154-6933-8
- 11-digit product format
- 551546933
- Labeler code
- 55154
- Product ID
- 55154-6933_38e8882e-539a-43cd-a916-48c69b8ac782
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- DAPAGLIFLOZIN
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Cardinal Health 107, LLC
- Application
- NDA202293
- Marketing category
- NDA
- Marketing start
- 2008-01-14
- Marketing end
- 2026-07-31
- Substance
- DAPAGLIFLOZIN PROPANEDIOL
- Active strength
- 10 mg/1
- Pharmacologic classes
- Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA]
- NDC exclude flag
- No
- Current FDA listing
- Yes
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 55154-6933 | 55154-6933-8 | D | Discontinued by firm | 2026-07-31 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N202293-001 | FARXIGA | DAPAGLIFLOZIN | 5MG | TABLET / ORAL | AB | RLD | 2014-01-08 |
| N202293-002 | FARXIGA | DAPAGLIFLOZIN | 10MG | TABLET / ORAL | AB | RLD, RS | 2014-01-08 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N202293-001 | AB |
| N202293-002 | AB |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N202293-001 | 6515117 | 2025-10-04 | U-2139 | Drug substance, Drug product | 2014-02-05 |
| N202293-001 | 6515117 | 2025-10-04 | U-493 | Drug substance, Drug product | 2014-02-05 |
| N202293-001 | 6515117*PED | 2026-04-04 | Pediatric extension | ||
| N202293-001 | 8329648 | 2026-08-18 | U-2139 | 2017-11-15 | |
| N202293-001 | 8329648 | 2026-08-18 | U-2212 | 2017-11-15 | |
| N202293-001 | 8329648 | 2026-08-18 | U-2213 | 2017-11-15 | |
| N202293-001 | 8906851 | 2026-08-18 | U-2139 | 2017-11-15 | |
| N202293-001 | 8329648*PED | 2027-02-18 | Pediatric extension | ||
| N202293-001 | 8906851*PED | 2027-02-18 | Pediatric extension | ||
| N202293-001 | 8501698 | 2027-06-20 | U-493 | Drug product | 2014-02-05 |
| N202293-001 | 8501698*PED | 2027-12-20 | Pediatric extension | ||
| N202293-001 | 8221786 | 2028-03-21 | Drug product | 2014-02-05 | |
| N202293-001 | 8361972 | 2028-03-21 | U-2139 | 2014-02-05 | |
| N202293-001 | 8361972 | 2028-03-21 | U-493 | 2014-02-05 | |
| N202293-001 | 8716251 | 2028-03-21 | Drug product | 2014-06-02 | |
| N202293-001 | 7851502 | 2028-08-19 | Drug product | 2014-02-05 | |
| N202293-001 | 8221786*PED | 2028-09-21 | Pediatric extension | ||
| N202293-001 | 8361972*PED | 2028-09-21 | Pediatric extension | ||
| N202293-001 | 8716251*PED | 2028-09-21 | Pediatric extension | ||
| N202293-001 | 7851502*PED | 2029-02-19 | Pediatric extension | ||
| N202293-001 | 7919598 | 2029-12-16 | Drug substance | 2014-02-05 | |
| N202293-001 | 8721615 | 2030-01-18 | Drug product, Delist requested | 2017-11-15 | |
| N202293-001 | 8685934 | 2030-05-26 | U-1522 | 2014-06-25 | |
| N202293-001 | 7919598*PED | 2030-06-16 | Pediatric extension | ||
| N202293-001 | 8721615*PED | 2030-07-18 | Pediatric extension | ||
| N202293-001 | 8685934*PED | 2030-11-26 | Pediatric extension | ||
| N202293-002 | 6515117 | 2025-10-04 | U-2139 | Drug substance, Drug product | 2014-02-05 |
| N202293-002 | 6515117 | 2025-10-04 | U-493 | Drug substance, Drug product | 2014-02-05 |
| N202293-002 | 6515117*PED | 2026-04-04 | Pediatric extension | ||
| N202293-002 | 8329648 | 2026-08-18 | U-2139 | 2017-11-15 | |
| N202293-002 | 8329648 | 2026-08-18 | U-2212 | 2017-11-15 | |
| N202293-002 | 8329648 | 2026-08-18 | U-2213 | 2017-11-15 | |
| N202293-002 | 8906851 | 2026-08-18 | U-2139 | 2017-11-15 | |
| N202293-002 | 8329648*PED | 2027-02-18 | Pediatric extension | ||
| N202293-002 | 8906851*PED | 2027-02-18 | Pediatric extension | ||
| N202293-002 | 8501698 | 2027-06-20 | U-493 | Drug product | 2014-02-05 |
| N202293-002 | 8501698*PED | 2027-12-20 | Pediatric extension | ||
| N202293-002 | 8221786 | 2028-03-21 | Drug product | 2014-02-05 | |
| N202293-002 | 8361972 | 2028-03-21 | U-2139 | 2014-02-05 | |
| N202293-002 | 8361972 | 2028-03-21 | U-493 | 2014-02-05 | |
| N202293-002 | 8716251 | 2028-03-21 | Drug product | 2014-06-02 | |
| N202293-002 | 7851502 | 2028-08-19 | Drug product | 2014-02-05 | |
| N202293-002 | 8221786*PED | 2028-09-21 | Pediatric extension | ||
| N202293-002 | 8361972*PED | 2028-09-21 | Pediatric extension | ||
| N202293-002 | 8716251*PED | 2028-09-21 | Pediatric extension | ||
| N202293-002 | 7851502*PED | 2029-02-19 | Pediatric extension | ||
| N202293-002 | 7919598 | 2029-12-16 | Drug substance | 2014-02-05 | |
| N202293-002 | 8721615 | 2030-01-18 | Drug product, Delist requested | 2017-11-15 | |
| N202293-002 | 8685934 | 2030-05-26 | U-1522 | 2014-06-25 | |
| N202293-002 | 7919598*PED | 2030-06-16 | Pediatric extension | ||
| N202293-002 | 8721615*PED | 2030-07-18 | Pediatric extension | ||
| N202293-002 | 8685934*PED | 2030-11-26 | Pediatric extension | ||
| N202293-002 | 11826376 | 2039-07-18 | U-3766 | 2023-12-19 | |
| N202293-002 | 12472194 | 2039-07-18 | U-4346 | 2025-12-11 | |
| N202293-002 | 11826376*PED | 2040-01-18 | Pediatric extension | ||
| N202293-002 | 12472194*PED | 2040-01-18 | Pediatric extension | ||
| N202293-002 | 10973836 | 2040-03-09 | U-3127 | 2021-04-21 | |
| N202293-002 | 11903955 | 2040-03-09 | U-3825 | 2024-03-13 | |
| N202293-002 | 10973836*PED | 2040-09-09 | Pediatric extension | ||
| N202293-002 | 11903955*PED | 2040-09-09 | Pediatric extension | ||
| N202293-002 | 12213988 | 2041-04-01 | U-4140 | 2025-03-04 | |
| N202293-002 | 12409186 | 2041-04-01 | U-4140 | 2025-09-29 | |
| N202293-002 | 12213988*PED | 2041-10-01 | Pediatric extension | ||
| N202293-002 | 12409186*PED | 2041-10-01 | Pediatric extension |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N202293-001 | M-298 | 2026-05-08 |
| N202293-001 | PED | 2026-11-08 |
| N202293-001 | NPP | 2027-06-12 |
| N202293-001 | PED | 2027-12-12 |
| N202293-002 | M-298 | 2026-05-08 |
| N202293-002 | PED | 2026-11-08 |
| N202293-002 | NPP | 2027-06-12 |
| N202293-002 | PED | 2027-12-12 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | FARXIGA | 5MG | TABLET / ORAL | AB | RLD | 2014-01-08 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | FARXIGA | 10MG | TABLET / ORAL | AB | RLD, RS | 2014-01-08 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | AB | 1 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 6515117 | 2025-10-04 | U-493 | Drug substance, Drug product | 2014-02-05 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 6515117 | 2025-10-04 | U-2139 | Drug substance, Drug product | 2014-02-05 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 6515117*PED | 2026-04-04 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8329648 | 2026-08-18 | U-2213 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8329648 | 2026-08-18 | U-2139 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8329648 | 2026-08-18 | U-2212 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8906851 | 2026-08-18 | U-2139 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8329648*PED | 2027-02-18 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8906851*PED | 2027-02-18 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8501698 | 2027-06-20 | U-493 | Drug product | 2014-02-05 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8501698*PED | 2027-12-20 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8221786 | 2028-03-21 | Drug product | 2014-02-05 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8361972 | 2028-03-21 | U-2139 | 2014-02-05 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8361972 | 2028-03-21 | U-493 | 2014-02-05 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8716251 | 2028-03-21 | Drug product | 2014-06-02 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 7851502 | 2028-08-19 | Drug product | 2014-02-05 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8221786*PED | 2028-09-21 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8361972*PED | 2028-09-21 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8716251*PED | 2028-09-21 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 7851502*PED | 2029-02-19 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 7919598 | 2029-12-16 | Drug substance | 2014-02-05 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8721615 | 2030-01-18 | Drug product, Delist requested | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8685934 | 2030-05-26 | U-1522 | 2014-06-25 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 7919598*PED | 2030-06-16 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8721615*PED | 2030-07-18 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | 8685934*PED | 2030-11-26 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 6515117 | 2025-10-04 | U-2139 | Drug substance, Drug product | 2014-02-05 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 6515117 | 2025-10-04 | U-493 | Drug substance, Drug product | 2014-02-05 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 6515117*PED | 2026-04-04 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8329648 | 2026-08-18 | U-2139 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8329648 | 2026-08-18 | U-2212 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8329648 | 2026-08-18 | U-2213 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8906851 | 2026-08-18 | U-2139 | 2017-11-15 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8329648*PED | 2027-02-18 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8906851*PED | 2027-02-18 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8501698 | 2027-06-20 | U-493 | Drug product | 2014-02-05 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8501698*PED | 2027-12-20 | Pediatric extension | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8221786 | 2028-03-21 | Drug product | 2014-02-05 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8361972 | 2028-03-21 | U-2139 | 2014-02-05 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | 8361972 | 2028-03-21 | U-493 | 2014-02-05 | a50c72e98297… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | M-298 | 2026-05-08 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | PED | 2026-11-08 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | NPP | 2027-06-12 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-001 | PED | 2027-12-12 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | M-298 | 2026-05-08 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | PED | 2026-11-08 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | NPP | 2027-06-12 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202293-002 | PED | 2027-12-12 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| FARXIGA | DAPAGLIFLOZIN | A-S Medication Solutions | 01f90c94-71cb-4a1f-81ff-8004b850529b | 2026-07-10 | Warnings, Adverse reactions | 202293 NDA202293 |
| FARXIGA | DAPAGLIFLOZIN | AstraZeneca Pharmaceuticals LP | 72ad22ae-efe6-4cd6-a302-98aaee423d69 | 2026-06-03 | Warnings, Adverse reactions | 202293 NDA202293 |
| DAPAGLIFLOZIN | DAPAGLIFLOZIN | Prasco Laboratories | 3aba33aa-f8c6-4b10-85c8-dfa14578d07c | 2026-06-03 | Warnings, Adverse reactions | 202293 NDA202293 |
| FARXIGA | DAPAGLIFLOZIN | REMEDYREPACK INC. | ef9e9c8c-5460-4193-952a-0c249dd071bd | 2026-04-24 | Warnings, Adverse reactions | 202293 NDA202293 |
| DAPAGLIFLOZIN | DAPAGLIFLOZIN | Bryant Ranch Prepack | 979205ee-b0b8-4483-ae61-f283f750bb7f | 2024-08-08 | Warnings, Adverse reactions | 202293 NDA202293 |
| DAPAGLIFLOZIN | DAPAGLIFLOZIN | A-S Medication Solutions | 82cdd5ad-df2b-4bdd-a3a6-a059040100b4 | 2024-06-28 | Warnings, Adverse reactions | 202293 NDA202293 |
| DAPAGLIFLOZIN | DAPAGLIFLOZIN | A-S Medication Solutions | 87521963-0d2a-4a2a-89c6-d50e8582419e | 2024-06-28 | Warnings, Adverse reactions | 202293 NDA202293 |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c30aab5e-c89f-4b59-83b1-99a940b63351 | Product name | 1 | 20200925 |
| 1dc427fa-8c3b-4309-981e-ea1ff01326e5 | Product name | 1 | 20190731 |
| 85b4e38c-4488-4e48-919e-244e107d9bd9 | Product name | 2 | 20190731 |
| 5ec207a9-fa56-4ff7-8fae-9a7d9a6bf52c | Product name | 2 | 20170824 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 55154-6933-8 | FARXIGA | 840 in 1 BOTTLE, PLASTIC | TABLET, FILM COATED | 840 | 20 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 55154-6933 | FARXIGA (DAPAGLIFLOZIN) TABLET, FILM COATED [CARDINAL HEALTH 107, LLC] | 20 | Current NDC, Legacy NDC, 1 package rows | 20240901_40cc4f5d-bcf6-4016-9d1e-838bbc4bdddc.zip |
DailyMed RxNorm Mappings#
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 55154-6933-8 | 55154693308 | 840 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55154-6933-8) | 2015-01-05 | 2026-07-31 | No | No | Current |